Literature DB >> 23735007

Will people change their vector-control practices in the presence of an imperfect dengue vaccine?

T M Q R Boccia1, M N Burattini1, F A B Coutinho1, E Massad1.   

Abstract

Human behaviours, which are influenced by social, cultural, economic and political factors, can increase or decrease the risk of dengue infection, depending on the relationship with the insect vector. Because no vaccine is currently available, the spread of dengue can only be curtailed by controlling vector populations (Aedes aegypti and others) and by protecting individuals. This study tested the hypothesis that dengue-affected populations are likely to relax their vector-control habits if a potentially protective vaccine becomes available. The hypothesis was tested using two approaches: a mathematical model designed to describe dengue transmission and an empirical field test in which the local population of an endemic area was interviewed about their vector-control habits given the presence of a theoretical vaccine. The model demonstrated that depending on the level of vector-control reduction, there is a threshold in vaccine efficacy below which it is better not to introduce the vaccine. The interview showed that people who were informed that a very effective vaccine is available would reduce their vector-control habits significantly compared to a group that was informed that the vaccine is not very effective.

Entities:  

Mesh:

Year:  2013        PMID: 23735007      PMCID: PMC9151158          DOI: 10.1017/S0950268813001350

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  18 in total

1.  Fuzzy logic and measles vaccination: designing a control strategy.

Authors:  E Massad; M N Burattini; N R Ortega
Journal:  Int J Epidemiol       Date:  1999-06       Impact factor: 7.196

2.  Threshold conditions for a non-autonomous epidemic system describing the population dynamics of dengue.

Authors:  F A B Coutinho; M N Burattini; L F Lopez; E Massad
Journal:  Bull Math Biol       Date:  2006-09-02       Impact factor: 1.758

3.  Modelling the control strategies against dengue in Singapore.

Authors:  M N Burattini; M Chen; A Chow; F A B Coutinho; K T Goh; L F Lopez; S Ma; E Massad
Journal:  Epidemiol Infect       Date:  2007-05-31       Impact factor: 2.451

4.  Designing a vaccination strategy against dengue.

Authors:  Marcos Amaku; Laurent Coudeville; Eduardo Massad
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2012-10       Impact factor: 1.846

5.  Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.

Authors:  Arunee Sabchareon; Derek Wallace; Chukiat Sirivichayakul; Kriengsak Limkittikul; Pornthep Chanthavanich; Saravudh Suvannadabba; Vithaya Jiwariyavej; Wut Dulyachai; Krisana Pengsaa; T Anh Wartel; Annick Moureau; Melanie Saville; Alain Bouckenooghe; Simonetta Viviani; Nadia G Tornieporth; Jean Lang
Journal:  Lancet       Date:  2012-09-11       Impact factor: 79.321

6.  Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development.

Authors:  Annelies Wilder-Smith; Eng-Eong Ooi; Subhash G Vasudevan; Duane J Gubler
Journal:  Curr Infect Dis Rep       Date:  2010-05       Impact factor: 3.725

7.  Control of aedes vectors of dengue in three provinces of Vietnam by use of Mesocyclops (Copepoda) and community-based methods validated by entomologic, clinical, and serological surveillance.

Authors:  Brian H Kay; Vu Sinh Nam; Tran Van Tien; Nguyen Thi Yen; Tran Vu Phong; Vu Thi Bich Diep; Truong Uyen Ninh; Ahmet Bektas; John G Aaskov
Journal:  Am J Trop Med Hyg       Date:  2002-01       Impact factor: 2.345

8.  Rubella seroepidemiology in a non-immunized population of São Paulo State, Brazil.

Authors:  R S De Azevedo Neto; A S Silveira; D J Nokes; H M Yang; S D Passos; M R Cardoso; E Massad
Journal:  Epidemiol Infect       Date:  1994-08       Impact factor: 2.451

9.  Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore.

Authors:  Yee Sin Leo; Anneliese Wilder-Smith; Sophia Archuleta; Lynette P Shek; Chia-Yin Chong; Hoe Nam Leong; Chian Yong Low; May-Lin Helen Oh; Alain Bouckenooghe; T Anh Wartel; Denis Crevat
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

10.  Controlling dengue with vaccines in Thailand.

Authors:  Dennis L Chao; Scott B Halstead; M Elizabeth Halloran; Ira M Longini
Journal:  PLoS Negl Trop Dis       Date:  2012-10-25
View more
  5 in total

1.  Impact of combined vector-control and vaccination strategies on transmission dynamics of dengue fever: a model-based analysis.

Authors:  Gerhart Knerer; Christine S M Currie; Sally C Brailsford
Journal:  Health Care Manag Sci       Date:  2013-12-27

2.  Mass trapping with MosquiTRAPs does not reduce Aedes aegypti abundance.

Authors:  Carolin Marlen Degener; Tatiana Mingote Ferreira de Ázara; Rosemary Aparecida Roque; Susanne Rösner; Eliseu Soares Oliveira Rocha; Erna Geessien Kroon; Cláudia Torres Codeço; Aline Araújo Nobre; Jörg Johannes Ohly; Martin Geier; Álvaro Eduardo Eiras
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-04-28       Impact factor: 2.743

3.  Integrating Transgenic Vector Manipulation with Clinical Interventions to Manage Vector-Borne Diseases.

Authors:  Kenichi W Okamoto; Fred Gould; Alun L Lloyd
Journal:  PLoS Comput Biol       Date:  2016-03-10       Impact factor: 4.475

Review 4.  Operations research in global health: a scoping review with a focus on the themes of health equity and impact.

Authors:  Beverly D Bradley; Tiffany Jung; Ananya Tandon-Verma; Bassem Khoury; Timothy C Y Chan; Yu-Ling Cheng
Journal:  Health Res Policy Syst       Date:  2017-04-18

5.  Migration rate estimation in an epidemic network.

Authors:  M Núñez-López; L Alarcón Ramos; J X Velasco-Hernández
Journal:  Appl Math Model       Date:  2020-09-12       Impact factor: 5.129

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.